Business Description
Founded in 2017 and headquartered in Zug, Switzerland, Oculis Holding AG is a pharmaceutical company focused on developing new treatments for eye and neurological conditions. Its three main drug candidates target diabetic macular edema, dry eye disease, and a range of conditions involving nerve damage in the eye, including glaucoma and optic neuritis. Each candidate is currently being tested in mid-to-late stage clinical trials.
